Skip to main content
Category

Carousel Slider

UCI MIND faculty finds connection between air pollution from traffic and Alzheimer’s disease

By Carousel Slider, In the News, UCI MIND

Masashi Kitazawa, Associate Professor of Environmental and Occupational Health, and his team found exposure to traffic-related air pollution led to memory loss and cognitive decline and triggered neurological pathways associated with the onset of Alzheimer’s disease. Read the article here.

The post UCI MIND faculty finds connection between air pollution from traffic and Alzheimer’s disease appeared first on UCI MIND.

Read More

And now, the FDA approves a medication for behavioral symptoms of Alzheimer’s disease

By Carousel Slider, In the News, UCI MIND

May 12, 2023–Brexpiprazole has now been approved by the FDA for the treatment of agitation in Alzheimer’s dementia.  Agitated behaviors are common in those with moderate or advanced Alzheimer’s dementia and these symptoms contribute substantially to caregiver burden, institutionalization, and faster cognitive decline.  Yesterday’s decision marks the first approval in the United States of a medication for these symptoms. The approval was based on the results of three 12-week treatment studies.  The studies collectively showed modest reduction in the frequency of specific agitated behaviors and lower severity on a clinician-rated measure.  In one of the studies, 56% of those treated…

The post And now, the FDA approves a medication for behavioral symptoms of Alzheimer’s disease appeared first on UCI MIND.

Read More

Positive topline results announced for TRAILBLAZER 3

By Carousel Slider, In the News, UCI MIND

May 3, 2023–Eli Lilly and company announced today (https://investor.lilly.com/news-releases/news-release-details/lillys-donanemab-significantly-slowed-cognitive-and-functional) the positive topline results from their Phase 3 clinical trial of donanemab, a monoclonal antibody that rapidly lowers beta amyloid levels in the brain of people with Alzheimer’s disease. The release indicated that patients treated with donanemab experienced significantly slower cognitive and functional decline, compared to those receiving placebo, over 18 months. The primary outcome was a composite measure known as the integrated Alzheimer’s Disease Rating Scale (iADRS, a tool that borrows pieces of other instruments to look at elements key in early disease) and was reported as demonstrating a 35%…

The post Positive topline results announced for TRAILBLAZER 3 appeared first on UCI MIND.

Read More

Dementia doubles in Orange County in less than a decade – UCI MIND Director weighs in

By Carousel Slider, In the News, UCI MIND

New number crunching from the Alzheimer’s Orange County estimates that the number of folks enduring this sort of heartbreak has essentially doubled since 2014 in the O.C. That’s a startling jump, from 84,000 to 164,000 people, which works out to about 5% of our total population. … “The new number is believable, especially if a difference from the previous estimate is the inclusion of mild cognitive impairment as a category,” said Dr. Joshua D. Grill, Professor of Neurobiology & Behavior and noted Alzheimer’s researcher at UC Irvine . “Orange County is ‘grayer’ than the rest of the country, so we do…

The post Dementia doubles in Orange County in less than a decade – UCI MIND Director weighs in appeared first on UCI MIND.

Read More

UCI MIND faculty named one of the top inspirational Black women in medicine

By Carousel Slider, Commentary, In the News, UCI MIND

UCI MIND faculty member and professor in the School of Public Health,  Karen D. Lincoln, PhD, MSW, MA, FGSA, is featured in Authority Magazine as being one of the top inspirational Black women in medicine. Read the full interview here To learn more about Dr. Lincoln’s research to address health disparities in Black communities, visit her faculty profile or her website: Advocates for African American Elders  

The post UCI MIND faculty named one of the top inspirational Black women in medicine appeared first on UCI MIND.

Read More

Inaugural Recipient of the UCI MIND Joan and Don Beall Scholar Award

By Carousel Slider, In the News, UCI MIND

The UC Irvine Institute for Memory Impairments and Neurological Disorders (UCI MIND) is pleased to announce that the inaugural recipient of the “UCI MIND Joan and Don Beall Scholar Award” is S. Ahmad Sajjadi, MD, PhD. Dr. Sajjadi is an Associate Professor of Neurology in the UCI School of Medicine. A clinician scientist with an established track record of studying different neurodegenerative pathologies across the aging spectrum, Dr. Sajjadi has demonstrated himself as an outstanding investigator and an important contributor to Alzheimer’s disease and related dementias (ADRD) research and clinical care at UCI. He is an investigator in the UCI Alzheimer’s…

The post Inaugural Recipient of the UCI MIND Joan and Don Beall Scholar Award appeared first on UCI MIND.

Read More

A4 Study Releases Negative Results

By Carousel Slider, Commentary, In the News, UCI MIND

The topline results for the Anti-Amyloid treatment in Asymptomatic Alzheimer’s disease (A4) study were released today (https://a4study.org). Unfortunately, the drug being investigated, solanezumab, failed to demonstrate a benefit in slowing memory changes in a population of individuals age 65-to-85 who met criteria for preclinical Alzheimer’s disease. Preclinical Alzheimer’s is a relatively new construct. It includes people who are older and have normal memory performance, but in whom biological tests suggest that the risk for Alzheimer’s disease dementia is high. The A4 study was among the first ever preclinical AD trials, boldly blazing a trail that has now been followed by…

The post A4 Study Releases Negative Results appeared first on UCI MIND.

Read More

UCI faculty member awarded grant to study patient reactions to Alzheimer’s disease diagnoses

By Carousel Slider, In the News, UCI MIND

Dr. Joshua Grill and colleagues at the University of Pittsburgh have been awarded a 3.5 million dollar grant by the National Institute on Aging to advance the field’s understanding of real-world patient and family member reactions to biomarker-informed Alzheimer’s disease and related disorders (ADRD) diagnoses and to provide critical information for directing post-diagnostic resources to monitor and support those most in need. Read the full news story about this important research here  

The post UCI faculty member awarded grant to study patient reactions to Alzheimer’s disease diagnoses appeared first on UCI MIND.

Read More
English